Back to search results

Phase II Study of Pirtobrutinib, Venetoclax, and Obinutuzumab for Relapsed CLL/SLL

This study is looking at a combination of three drugs – pirtobrutinib, venetoclax, and obinutuzumab – for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after previous treatment. The goal is to see if this combination can help control the disease. You may be able to join if you are 18 or older, have CLL/SLL that needs treatment again, and can take medications by mouth. Researchers will measure how safe the treatment is and how many people have very low levels of cancer cells in their bone marrow after about a year. This study plans to enroll 40 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06967610

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~40 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:PirtobrutinibVenetoclaxObinutuzumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events
Measured over Through study completion; an average of 1 year.

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia (SLL)

Explore related trials

Chronic Lymphocytic LeukemiaLymphoid Leukemia

NCT06967610

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Alessandra Ferrajoli, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Alessandra Ferrajoli, MD
[email protected]
713-792-2063
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

active graft versus host disease (GVHD);
cytopenia from incomplete blood cell count recovery post-transplant;
need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity \> Grade 1 from CAR-T therapy;
ongoing immunosuppressive therapy (\> 20 mg prednisone or equivalent daily). 12. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia \[AIHA\], idiopathic thrombocytopenic purpura \[ITP\]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts. 13. Participants who experienced grade \>3 arrhythmia on prior treatment with BTK inhibitor. 14. Significant cardiovascular disease, defined as any of the following:

What this trial measures

  • Safety and adverse eventsThrough study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5